Announcements Trials

Browse Landscape

Phase

Phase 1/2 4 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 7 Leukemia, Lymphocytic, Chronic, B-Cell 4 Lymphoma, B-Cell 3 Lymphoma 3 Lymphoma, Non-Hodgkin 2 Lymphoma, Mantle-Cell 2 Lymphoma, Follicular 2 Lymphoma, B-Cell, Marginal Zone 2 Burkitt Lymphoma 2 Recurrence 1 Pyloric Stenosis, Hypertrophic 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Leukemia, Prolymphocytic 1 Hodgkin Disease 1 Hematologic Neoplasms 1

Interventions

Cyclophosphamide 58 Dexamethasone 50 Rituximab 39 Peripheral Blood Stem Cell Transplantation 29 Paclitaxel 29 Lenalidomide 28 fludarabine phosphate 27 Gemcitabine 26 Etoposide 26 Bortezomib 26 Cytarabine 25 Busulfan 24 pembrolizumab 21 Radiotherapy 21 Bevacizumab 21 Carboplatin 20 Mycophenolic Acid 19 Melphalan 19 Cisplatin 19 Filgrastim 18 pomalidomide 17 fludarabine 17 Oxaliplatin 17 Antilymphocyte Serum 17 Cyclosporine 16 Tacrolimus 15 Methotrexate 15 Whole-Body Irradiation 14 Methylprednisolone 13 Bendamustine Hydrochloride 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Recurrence × tafasitamab × Clear all

NCT07126236 2025-08-17

REPIFIR

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Phase 2 Recruiting

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡